Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.

ABSTRACT:

Background

Growing evidence suggests that blood eosinophil count is associated with patient responsiveness to inhaled corticosteroids (ICS). We performed post hoc predictive modeling on data from the FORWARD study and two replicate studies by Dransfield, to evaluate the relationships between baseline eosinophil count and the effect of ICS on exacerbations and lung function in patients with COPD.

Methods

The studies assessed ICS/long-acting β₂ agonist (LABA) combinations vs LABA alone. Using data from each study, we modeled COPD exacerbation rates, predose FEV₁, and St George's Respiratory Questionnaire score ([FORWARD only]) over a continuous range of eosinophils (0-1,000 eosinophils/µL in FORWARD, 0-993 eosinophils/µL in Dransfield).

Results

In

SUBMITTER: Siddiqui SH 

PROVIDER: S-EPMC6225850 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature